The gene expression test Oncotype DX® is intended for women with early-stage breast cancer. The test is used to determine the necessity of follow-up treatment with chemotherapy.
On August 11, 2021, the Dutch Healthcare Institute (ZIN) published the assessment of Oncotype DX®, which concluded that the use of the test complies with the criteria of "science and practice", and the test can be reimbursed from the basic health insurance package since August 10, 2021.
The Oncotype DX® test is reimbursed only in women with early-stage breast cancer and a clinically high risk who meet the following criteria:
- Age of 50 years and older; AND
- ER-positive or HER2-negative status; AND
- No nearby (regional) lymph node metastases (N0); AND
- Grade 1 tumor with a tumor size between 3.1 and 5 cm OR grade 2 tumor with a tumor size between 2.1 and 5 cm OR Grade 3 tumor with a tumor size between 1.1 and 2 cm.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).